SpectronRx to supply PET radiotracer for CereMark's clinical trials

By AuntMinnie.com staff writers

May 5, 2023 -- CereMark Pharma has inked a supply deal with SpectronRx for the use of the F-18 flornaptitril in clinical trials in patients with neurodegenerative disease.

F-18 flornaptitril (formerly known as F-18 FDDNP) is an investigational new PET imaging tracer being studied for use in the management of Alzheimer's disease and chronic traumatic encephalopathy. Under the agreement, SpectronRx will manufacture the radiopharmaceutical for CereMark using a patented synthetic technique held by the company under license from the University of California, Los Angeles.

CereMark plans to use F‑18 flornaptitril in a phase III multi-site clinical study planned to start later this year, the company said.

Copyright © 2023 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking